BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch
Source: SeekingAlpha
2025-11-13 18:52:16 ET
More on BioAtla
- BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on BioAtla
- Historical earnings data for BioAtla
- Financial information for BioAtla
Read the full article on Seeking Alpha
For further details see:
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch
BioAtla Inc.
NASDAQ: BCAB
BCAB Trading
-4.29% G/L:
$3.35 Last:
89,341 Volume:
$3.51 Open:
BCAB Latest News
May 18, 2026 06:45:00 am
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
March 31, 2026 04:05:00 pm
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
BCAB Stock Data
$12,399,342
60,967,643
5.51%
17
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
